Solid Biosciences Inc.

Solid Biosciences Inc. (NASDAQ: SLDB) is a life sciences company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. The company was founded in 2013 and operates as a Delaware corporation. More information about the company is available at www.solidbiosciences.com.

The company's pipeline includes several investigational gene transfer candidates at varying stages of development. SGT-003, the lead neuromuscular program, is designed to treat Duchenne muscular dystrophy by delivering a synthetic microdystrophin transgene using a novel AAV capsid called POLARIS-101. SGT-212 targets Friedreich's ataxia through full-length frataxin gene replacement using dual-route administration combining intradentate nuclei infusion and intravenous delivery. In the cardiac space, SGT-501 addresses catecholaminergic polymorphic ventricular tachycardia through CASQ2 gene therapy, while SGT-601 targets TNNT2-mediated dilated cardiomyopathy. Additional preclinical programs include SGT-401 for BAG3-mediated dilated cardiomyopathy and SGT-701 for RBM20-mediated dilated cardiomyopathy.

Solid Biosciences operates as a clinical-stage biopharmaceutical company with no approved products or revenue from product sales. The company's business model centers on advancing its diverse pipeline through internal capabilities including a vector core, validated animal models, optimized expression cassettes, novel capsids, and regulatory expertise, complemented by collaborations with academic and clinical leaders. The company relies on third-party manufacturers for drug product supply using transient transfection manufacturing processes.

The company's intellectual property strategy involves owning and in-licensing patents, patent applications, know-how, and trade secrets related to gene therapy development. As of February 2026, Solid's patent portfolio includes both owned and in-licensed patent families covering its gene therapy programs and platform technologies. The company has received regulatory designations including Fast Track, Orphan Drug, and Rare Pediatric Disease designations for multiple candidates, as well as an Innovation Passport from the UK Innovative Licensing and Access Pathway for SGT-003.